Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)

Patent metadata

Field	Value
Publication number	US-11028446-B2
Application number	US-201916421788-A
Country	US
Kind code	B2
Filing date	May 24, 2019
Priority date	May 11, 2009
Publication date	Jun 8, 2021
Grant date	Jun 8, 2021

Abstract

Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described.

First claim

The invention claimed is:

1. A method for treating an oncological disorder in a human, comprising:
administering Coenzyme Q10 (CoQ10) to the human such that treatment occurs, wherein the CoQ10 is in its oxidized form and has a purity between 95% and 100%, and wherein administration of the CoQ10 to the human results in an increase of CoQ10 in the oxidized form in the human, wherein the oncological disorder is selected from the group consisting of pancreatic carcinoma, hepatocellular carcinoma, Ewing's sarcoma, breast cancer, brain cancer, astrocytoma, neuroendocrine cancer, colon cancer, lung cancer, osteosarcoma, prostate cancer, ovarian cancer, Squamous cell Carcinoma, Basal Cell Carcinoma and non-Hodgkin's Lymphoma.

2. The method of claim 1 , wherein the CoQ10 induces apoptosis or cell death mechanism in a cancerous cell of the oncological disorder.

3. The method of claim 1 , wherein the Coenzyme Q10 is administered such that it is maintained in its oxidized form during treatment.

4. The method of claim 1 , further comprising a treatment regimen selected from the group consisting of surgery, radiation, hormone therapy, antibody therapy, therapy with growth factors, cytokines, and chemotherapy.

5. The method of claim 1 , wherein the Coenzyme Q10 is administered by intravenous administration.

6. The method of claim 1 , wherein the Coenzyme Q10 is administered by topical administration.

7. The method of claim 1 , wherein the Coenzyme Q10 is administered with an additional therapeutic agent.

8. The method of claim 7 , wherein the Coenzyme Q10 is administered concurrently with the additional therapeutic agent.

9. The method of claim 7 , wherein the Coenzyme Q10 is administered prior to administration of the additional therapeutic agent.

10. The method of claim 7 , wherein the Coenzyme Q10 is administered subsequent to administration of the additional therapeutic agent.

11. The method of claim 7 , wherein the additional therapeutic agent is a chemotherapeutic agent.

12. The method of claim 11 , wherein the chemotherapeutic agent is selected from the group consisting of amifostine (ethyol), cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carrnustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), doxorubicin lipo (doxil), gemcitabine (gemzar), daunorubicin, daunorubicin lipo (daunoxome), procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil (5-FU), vinblastine, vincristine, bleomycin, paclitaxel (taxol), docetaxel (taxotere), aldesleukin, asparaginase, busulfan, carboplatin, cladribine, camptothecin, CPT-I1, 10-hydroxy-7-ethyl-camptothecin (SN38), dacarbazine, S-I capecitabine, ftorafur, 5′deoxyflurouridine, UFT, eniluracil, deoxycytidine, 5-azacytosine, 5-azadeoxycytosine, allopurinol, 2-chloro adenosine, trimetrexate, aminopterin, methylene-10-deazaaminopterin (MDAM), oxaplatin, picoplatin, tetraplatin, satraplatin, platinum-DACH, ormaplatin, CI-973, JM-216, and analogs thereof, epirubicin, etoposide phosphate, 9- aminocamptothecin, 10, 11-methylenedioxycamptothecin, karenitecin, 9-nitrocamptothecin, TAS 103, vindesine, L-phenylalanine mustard, ifosphamidemefosphamide, perfosfamide, trophosphamide carmustine, semustine, epothilones A-E, tomudex, 6-mercaptopurine, 6-thioguanine, amsacrine, etoposide phosphate, karenitecin, acyclovir, valacyclovir, ganciclovir, amantadine, rimantadine, lamivudine, zidovudine, bevacizumab, trastuzumab, rituximab, 5-Fluorouracil, Capecitabine, Pentostatin, Trimetrexate, Cladribine, floxuridine, fludarabine, hydroxyurea, ifosfamide, idarubicin, mesna, irinotecan, mitoxantrone, topotecan, leuprolide, megestrol, melphalan, mercaptopurine, plicamycin, mitotane, pegaspargase, pentostatin, pipobroman, plicamycin, streptozocin, tamoxifen, teniposide, testolactone, thioguanine, thiotepa, uracil mustard, vinorelbine, chlorambucil, and combinations thereof.

13. The method of claim 1 , wherein the oncological disorder is pancreatic cancer.

14. The method of claim 1 , wherein the oncological disorder is brain cancer.

15. The method of claim 1 , wherein the CoQ10 is administered at a dose of at least 5 mg/kg.

Assignees

• Berg Llc

Inventors

• Narain Niven Rajin
• Mccook John Patrick

Classifications

• G01N33/5758 Primary

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• A61K31/00 Primary

  Medicinal preparations containing organic active ingredients · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• C12Q2600/136

  Screening for pharmacological compounds · CPC title

• G01N33/5735

  co-enzymes or co-factors, e.g. NAD or ATP · CPC title